SCHEMBL19987569

SCHEMBL19987569

CCCC(C)(C)c1ccc(OCC)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.41
BRD4 O60885 1/20 0.36
CCL2 P13500 1/20 0.36
KIF11 P52732 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
KMT2A Q03164 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
ALDH1A1 P00352 2/20 0.35
ATM Q13315 1/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
ESR2 Q92731 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HPGD P15428 1/20 0.35
PDK2 Q15119 2/20 0.35
FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19987524 0.87 NQO1 (0.43) NQO1MEN1NPC1KMT2AAPOBEC3G
SCHEMBL19987450 0.85 KIF11 (0.49) KIF11ALDH1A1CPS1CYP1A2
SCHEMBL18120375 0.83 NQO1 (0.46) NQO1BRD4CCL2KIF11MEN1
SCHEMBL19987506 0.83 PDE2A (0.43) KIF11TSHRTP53HPGDFFAR1
SCHEMBL18649480 0.78 RIPK1 (0.39) ALDH1A1CYP3A4
SCHEMBL19232083 0.75 HDAC3 (0.37) MEN1KMT2ATSHRTDP1CYP3A4
SCHEMBL21718395 0.73 PDK2 (0.40) MEN1NPC1KMT2ATP53MAPT
SCHEMBL1547853 0.73 NQO1 (0.56) NQO1MEN1NPC1KMT2AAPOBEC3G
SCHEMBL13334863 0.73 NQO1 (0.46) NQO1MEN1NPC1KMT2AAPOBEC3G
SCHEMBL5471152 0.72 KDM4E (0.35) NQO1MEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT NQO1 47/4885BRD4 608/4885CCL2 388/4885
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT NQO1 47/4885BRD4 608/4885CCL2 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.